September 4th 2023
In the interview, Alexander Helfand, MD reviewed the latest in gastrointestinal stromal tumor research, and hopes for the future.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Becerra Shares Treatment Considerations in 2 Gastrointestinal Case Studies
April 10th 2018Carlos Becerra, MD, recently shared the treatment considerations and decisions he makes when treating patients with metastatic colorectal cancer and hepatocellular carcinoma. Becerra, a medical oncologist at Texas Oncology, Baylor Charles A. Sammons Cancer Center, explained his treatment decisions based on 2 case scenarios during a <em>Targeted Oncology </em>live case-based peer perspectives presentation.
Read More
Top-Line Results Show Ramucirumab Improves Survival in Second-Line HCC
April 10th 2018Overall survival was extended in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein (AFP) who received second-line treatment with ramucirumab (Cyramza) versus placebo, according to findings from the phase III REACH-2 trial.
Read More
Sanjeevani Arora Receives Cancer Research Grant from Department of Defense
April 6th 2018The US Department of Defense has selected Sanjeevani Arora, PhD, as the recipient of the Peer Reviewed Cancer Research Program Career Development award and grant for fiscal year 2017. The grant will be used to fund clinical efforts benefiting both military and civilian patients.
Read More
T-VEC Injections Safe in Patients with Advanced-Stage Liver Metastases
March 29th 2018According to early results of an ongoing early-phase study presented at the 2018 Society of Interventional Radiology Annual Scientific Meeting, image-guided injections of talimogene laherparepvec immunotherapy (T-VEC, Imylgic) were deemed tolerable in patients with advanced-stage liver metastases.
Read More
Bendell Takes the Helm as Chief Development Officer at Sarah Cannon
March 22nd 2018Internationally renowned expert, Johanna C. Bendell, MD, has been promoted to chief development officer at Sarah Cannon. Her title responsibilities include developing and expanding physician, site, and Pharma relationships across the Sarah Cannon Network, thereby expanding the organization’s efforts to bring more qualitative treatment options to its patients.
Read More
Marshall Highlights Treatment Options for Left-Sided mCRC
March 16th 2018John Marshall, MD, recently discussed the treatment options and decisions he makes when treating patients with metastatic colorectal cancer. Marshall explained his treatment decisions based on 2 case scenarios during a <em>Targeted Oncology </em>live case-based peer perspectives presentation.
Read More
Nut Consumption Associated With Improved Survival in Colon Cancer, Study Finds
March 6th 2018According to results from the CALGB 8903 study published in the <em>Journal of Clinical Oncology, </em>there is an association between total nut intake and improved outcomes in patients with stage III colon cancer. Results of the study showed patients who ate at least 2 servings of nuts per week had superior disease-free survival and overall survival.
Read More
Pamrevlumab Granted Fast Track Designation by FDA for Locally Advanced Pancreatic Cancer
March 2nd 2018The FDA has granted a Fast Track designation to pamrevlumab for the treatment of patients with locally advanced, unresectable pancreatic cancer, according to FibroGen, the manufacturer of the first-in-class anti-CTGF antibody.
Read More
Published Data Supports Lenvatinib as Potential New HCC Treatment Option as FDA Weighs Approval
February 27th 2018According to findings from the phase III REFLECT trial now published online in the <em>Lancet,</em><sup> </sup>lenvatinib improved progression-free survival and was noninferior for overall survival compared with sorafenib for the frontline treatment of patients with unresectable hepatocellular carcinoma.
Read More
Louis Weiner to Join John Theurer Cancer Center Advisory Board
February 26th 2018Hackensack Meridian <em>Health</em> John Theurer Cancer Center at Hackensack University Medical Center has appointed Louis M. Weiner, MD, to its advisory board. Weiner is the director of the Georgetown Lombardi Cancer Center and director of the MedStar Georgetown Cancer Institute.
Read More
Overman Discusses Remaining Questions Following Nivolumab Results in MSI-H/dMMR mCRC
February 12th 2018Updated findings of the CheckMate-142 study presented by Michael J. Overman, MD, at the 2018 Gastrointestinal Cancers Symposium continued to support the use of nivolumab alone or in combination with ipilimumab for previously treated patients with DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.
Read More